restless legs syndrome

(redirected from Restless leg)
Also found in: Dictionary, Thesaurus, Medical, Financial.

restless legs syndrome

[‚rest·ləs ′legz ‚sin‚drōm]
(medicine)
A condition that is characterized by intense disagreeable feelings in the legs at rest and repose with compulsion to move the legs to get relief from these symptoms, peak onset usually occurs during middle age, and the disorder tends to become more severe with age.
References in periodicals archive ?
Augmentation of the restless legs syndrome with carbidopa/levadopa.
Pharmaceutical inhibitors of the enzyme, catechol-O-methyl transferase (COMT) have been used to help ease symptoms of restless leg syndrome.
Also, it will be important to evaluate whether effective treatments for restless legs syndrome can prevent adverse outcomes associated with LVH.
Insomnia, sleep apnea, restless leg syndrome, bruxism, narcolepsy and sleepwalking are all serious sleep disorders that possess negative-and sometimes fatal-health consequences.
Tum katilimcilara International Restless Legs Syndrome Study Group (IRLSSG) tarafindan 1995 yilinda kabul edilen hasta oykusune dayanan 4 soruluk minimal tani kriterleri anketi, dort soruya da evet cevabi veren katilimcilara, IRLSSG tarafindan 2002'de kabul edilen IRLSSG-SDO (siddet degerlendirme olcegi) anketi, HBS klinik belirtileri anketi uygulandi.
Thirty patients (aged 20-80 years; mean age, 56 years) with restless legs syndrome and a low-normal serum ferritin level (15-50 ng/ml; suggestive of low or borderline-low iron status) were randomly assigned to receive ferrous sulfate (325 mg twice a day) or pramipexole (0.
An oral appliance that advances a patient's lower jaw reduced episodes of obstructive sleep apnea, snoring, and restless legs symptoms, but it failed to improve daytime sleepiness or quality of life, according to researchers.
GlobalData's clinical trial report, "Restless Legs Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Restless Legs Syndrome clinical trial scenario.
The dopamine receptor agonist rotigotine significantly reduced symptoms of restless legs syndrome in a multicenter placebo-controlled trial.